FSH absorbed alike from muscle and under the skin in a 19-woman trial

Does intramuscular injection absorb faster than subcutaneous?

Not for recombinant FSH: in a randomized crossover trial, intramuscular and subcutaneous doses produced no significant difference in peak concentration, time to peak or total exposure ^[2]. Most peptide guidance substitutes folklore for data on this point.

Nineteen women received the same 300 IU dose of recombinant FSH by both routes, and researchers compared peak concentration, time to peak and total exposure (AUC) directly. No significant difference emerged between routes, even as body mass index ranged from 19.9 to 42.8 kg/m². AUC did decline with higher BMI, regardless of route ^[2].

The FSH trial is a real head-to-head test in a peptide hormone, and it shows route mattered less than assumed for that molecule. Switching route does not change the amount delivered. What can change is how fast the dose shows up in blood and how high the peak gets, which matters only for compounds with an acute, dose-related effect ^[6].

How does an injected peptide reach the bloodstream?

An injected peptide crosses the interstitial matrix, then enters circulation through blood capillaries or through lymphatic vessels that empty into the bloodstream. Molecular weight largely decides which of the two paths dominates.

Smaller peptides pass fairly efficiently into capillaries. For them, local blood flow at the injection site is a meaningful variable, and muscle is more richly perfused than subcutaneous fat.

Larger proteins, including antibody-scale molecules, are increasingly excluded from capillary pores and rely on lymphatic transport instead. On that route, the density of hyaluronan, a glycosaminoglycan in the interstitial space, acts as a physical barrier, and blood flow is not the limiting factor ^[6].

"Muscle absorbs faster" is therefore a claim about capillary-dominant molecules, not a universal property of injections. The analysis of how injection route effects vary by molecule follows the same logic across compounds.

Why do large proteins absorb slowly from under the skin?

Large proteins depend on lymphatic uptake, a slower route governed more by the interstitial matrix than by local blood flow ^[6]⁠^[3]. In rats, removing the interstitial hyaluronan barrier raised the bioavailability of a large monoclonal antibody after subcutaneous injection from 67% to 80% and increased its lymphatic recovery ^[3].

That experiment is direct evidence that the bottleneck for large molecules sits in the tissue matrix, not in perfusion rate ^[3]. Lymphatic drainage is also not a passive pipe. Knockout mouse work on a lymphatic-regulating receptor showed measurably delayed subcutaneous lymphatic drainage when the receptor was absent, so the lymphatic route is an actively regulated biological process with its own variability ^[5].

Does the injection site matter within subcutaneous tissue?

Injection site changes absorption even when every dose stays subcutaneous. A separate randomized crossover trial gave the identical FSH dose by abdominal and by vaginal subcutaneous injection and found different absorption profiles at the two sites ^[1].

"Subcutaneous" is not one uniform compartment. Site and local tissue environment can matter independently of the subcutaneous-versus-intramuscular question ^[1].

Can the FSH route result be applied to other peptides?

Applying the FSH result to a much smaller peptide, or to one with a different formulation, is a guess, not a fact. Most other peptides circulating in research and compounding contexts lack a comparably designed subcutaneous-versus-intramuscular crossover trial.

The evidence on route sits in tiers. At the top are the randomized crossover trials in FSH, the highest grade this topic gets ^[2]⁠^[1]. Below them sits mechanistic review work explaining why molecular weight and local perfusion are the plausible drivers ^[6], and animal data showing the matrix-and-lymphatics bottleneck can be manipulated directly ^[3].

How likely is a subcutaneous injection to reach muscle by accident?

Accidental intramuscular injection depends heavily on site and needle length: an 8 mm needle inserted straight in carried an estimated 25% intramuscular risk at the thigh ^[4]. Anatomical data answer this question better than any route rule.

Ultrasound measured skin-to-muscle distance directly across diverse adults, and it varied by body site, BMI and gender. Median distance ranged from about 10.9 mm at the thigh to about 16.9 mm at the buttock, and the shortest measured distances were under 5 mm at most sites ^[4].

Combined with needle length, those distances produce widely different real-world odds of hitting muscle unintentionally.

How should you choose a needle and site for a subcutaneous peptide?

A short needle in a fat-rich site, the abdomen over the thigh, minimizes the odds of landing in a tissue plane you did not intend ^[4]. The abdomen is a lower-risk site than the thigh for staying subcutaneous, and needle length does more work than most people assume. The guide to peptide injection needle length covers that choice in detail.

Before that choice, find roughly where the molecule sits on the size spectrum and whether route-comparison data exist for it. The anatomy data do not show whether an accidental intramuscular hit matters for the specific molecule in a vial. That question goes back to the size-and-perfusion logic, and for FSH, a peptide hormone tested head-to-head, route barely moved exposure ^[2].

What is still unknown about intramuscular versus subcutaneous peptides?

Most peptides sold in research or compounded form have never had a route-comparison trial run on them at all. The FSH data cannot be assumed to generalize to a molecule of a different molecular weight or formulation. Route matters as much as the molecule in the vial dictates, and for most peptides that has never been measured directly.

• Concentration and volume. None of the cited studies connects reconstitution concentration or injection volume to route sensitivity.
• Repeated dosing. No cited trial tested whether repeated dosing over weeks, rather than a single dose, changes the picture.
• Individual anatomy. Accidental intramuscular risk, documented for insulin-style subcutaneous therapy, varies between people even with identical technique, because it shifts with BMI, site and gender ^[4].

The same class-dependent logic, not a universal rule, should govern reconstitution technique, interpreting cloudiness in a vial and room-temperature tolerance. Each of those questions turns on the specific protein's structure and formulation and deserves its own evidence-based answer, not one borrowed from an unrelated compound.